How do we identify patients most likely to benefit from immune checkpoint blockade therapies? This month in Med, Wu and colleagues1identify that CCL19+mature dendritic cells correlated with responses to anti-PD-(L)1 immunotherapy in triple-negative breast cancer patients, suggesting the use of CCL19 as a biomarker to predict patient outcomes.